Key Highlights
- Even with this setback, Eli Lilly should remain the leader in the weight loss space.
- 10 stocks we like better than Eli Lilly › Competition in the weight loss market is heating up.
- The two leaders, Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), have robust pipelines, with several candidates recently approved or expected to be approved soon.
- One of them for Eli Lilly is orforglipron, an oral GLP-1 medicine.
- Although orforglipron looks promising, it recently experienced a setback that sent Eli Lilly's shares down by about 4% in one day.
